Gilead Sciences : GILD

All Gilead Sciences Articles

736 Articles

Jon C. Ogg | Sep 17, 2012 at 3:16 PM EDT

BofA Adds GE, Gilead, Regions and Valero to Most Attractive Buy List

Key research changes have been made in the last few days over at Bank of America/Merrill Lynch’s research coverage. The…

Trey Thoelcke | Sep 13, 2012 at 8:52 AM EDT

Short Interest in Biotech Wanes (ALXN, AMGN, ARNA, BIIB, CELG, DNDN, GILD, ILMN, ONXX, PCYC, REGN, VRTX, VVUS, IBB)

The short interest in biotech stocks is generally falling, judging by the short interest changes from August 31 settlement date…

Douglas A. McIntyre | Aug 28, 2012 at 6:32 AM EDT

Media Digest (8/28/2012) Reuters, WSJ, NYT, Bloomberg

Apple Inc. (NASDAQ: AAPL) pushes for a ban on eight Samsung phones. (Reuters) Best Buy Co. Inc. (NYSE: BBY) will…

Trey Thoelcke | Aug 27, 2012 at 8:10 AM EDT

Biotech: Vertex and VIVUS Draw Short Interest (ALXN, AMGN, ARNA, BIIB, CELG, DNDN, GILD, ILMN, ONXX, PCYC, REGN, VRTX, VVUS)

The short interest in biotech stocks is generally rising, judging by the short interest changes from August 15 settlement date…

Trey Thoelcke | Aug 10, 2012 at 9:51 AM EDT

Biotech: Dendreon and Regeneron Draw Short Interest

The short interest data is out from the July 31 settlement date and, with a couple of notable exceptions, short…

Jon C. Ogg | Aug 7, 2012 at 8:39 AM EDT

Top Analyst Upgrades and Downgrades (AMGN, AMT, AMAT, COH, DELL, FLEX, GILD, HPQ, KCG, LEAP, NTAP, SANM, SPLK, VE, VRTX, VVUS, WMT)

Jon OggThese are some of the top analyst upgrades, downgrades and initiations seen from Wall St. research calls this Tuesday…

Jon C. Ogg | Aug 2, 2012 at 11:47 AM EDT

Gilead Options & New High In Stock Bring Hope For Further Upside

Gilead Sciences Inc. (NASDAQ: GILD) is seeing shares surge today on news that Bristol-Myers Squibb Co. (NYSE: BMY) has run…

Paul Ausick | Jul 26, 2012 at 4:04 PM EDT

24/7 Wall St. Closing Bell — July 26, 2012: Market Jumps on ECB President’s Vow

The three major US stock indexes opened higher this morning following European Central Bank president Mario Draghi’s promise to “do…

Jon C. Ogg | Jul 24, 2012 at 1:43 PM EDT

How ‘At-Risk’ Is Gilead’s HIV/AIDS Drug Dominance? (GILD, MRK, GSK)

GileadGilead Sciences, Inc. (NASDAQ: GILD) has a product chest that includes Atripla, Truvada, Viread, Complera/Eviplera, and Emtriva for the treatment…

Jon C. Ogg | Jul 3, 2012 at 7:35 AM EDT

GlobeImmune Files For IPO, Cancer & Hepatitis with Great Partnerships

GlobeImmune, Inc. is the latest biotech to file for an initial public offering. Financial terms were not disclosed but the…

Jon C. Ogg | Apr 18, 2012 at 8:23 AM EDT

Key Biotech Issues To Watch (XBI, ANIK, BCRX, CBST, DNDN, GILD, ILMN, TRGT)

Biotech is a sector which is often mixed with a hodge-podge of winners and losers based on news flow from…

Jon C. Ogg | Apr 4, 2012 at 1:28 PM EDT

Abbott’s Hep-C Pressures All Hep-C Rivals (ABT, RIGL, GILD, VRTX, IDIX)

News from Abbott Laboratories (NYSE: ABT) on its positive Phase II study results from two different interferon-free hepatitis C treatment…

Jon C. Ogg | Feb 25, 2012 at 7:31 AM EST

24/7 Wall St. Top Analyst Calls of the Week (BX, APO, CMA, DELL, DANG, EXM, FSLR, GILD, LVLT, ERIC, MAR, ORCL, SUN, VVUS, WBMD)

Jon OggEach weekend we review the many analyst calls we track during the week. Some turn out to be very…

Paul Ausick | Feb 22, 2012 at 4:07 PM EST

24/7 Wall St. Closing Bell (AAPL, DELL, MOS, GILD, DNDN, BAS, CYH, LOPE, RRC, CETV, CHS, DLTR, GRMN, NG, RRD, TOL, HSTM, FIRE, THLD, NFX, CELL)

US equities markets opened lower this morning following surprisingly weak manufacturing reports from Europe and China. Fitch Ratings’ downgrade of…

Jon C. Ogg | Feb 22, 2012 at 8:05 AM EST

Top Analyst Upgrades & Downgrades (ASX, AAPL, BX, BRCM, CIEN, CMA, DELL, DNDN, DANG, GILD, MDT, MOS, EDU, SPIL, TSM)

Jon OggThese are some of this Wednesday’s top analyst upgrades, downgrades, and initiations seen in Wall Street research calls. Advanced…

1 … 42 43 44 45 46 … 50

Gilead Sciences : GILD

All Gilead Sciences Articles

BofA Adds GE, Gilead, Regions and Valero to Most Attractive Buy List

Short Interest in Biotech Wanes (ALXN, AMGN, ARNA, BIIB, CELG, DNDN, GILD, ILMN, ONXX, PCYC, REGN, VRTX, VVUS, IBB)

Media Digest (8/28/2012) Reuters, WSJ, NYT, Bloomberg

Biotech: Vertex and VIVUS Draw Short Interest (ALXN, AMGN, ARNA, BIIB, CELG, DNDN, GILD, ILMN, ONXX, PCYC, REGN, VRTX, VVUS)

Biotech: Dendreon and Regeneron Draw Short Interest

Top Analyst Upgrades and Downgrades (AMGN, AMT, AMAT, COH, DELL, FLEX, GILD, HPQ, KCG, LEAP, NTAP, SANM, SPLK, VE, VRTX, VVUS, WMT)

Gilead Options & New High In Stock Bring Hope For Further Upside

24/7 Wall St. Closing Bell — July 26, 2012: Market Jumps on ECB President’s Vow

How ‘At-Risk’ Is Gilead’s HIV/AIDS Drug Dominance? (GILD, MRK, GSK)

GlobeImmune Files For IPO, Cancer & Hepatitis with Great Partnerships

Key Biotech Issues To Watch (XBI, ANIK, BCRX, CBST, DNDN, GILD, ILMN, TRGT)

Abbott’s Hep-C Pressures All Hep-C Rivals (ABT, RIGL, GILD, VRTX, IDIX)

24/7 Wall St. Top Analyst Calls of the Week (BX, APO, CMA, DELL, DANG, EXM, FSLR, GILD, LVLT, ERIC, MAR, ORCL, SUN, VVUS, WBMD)

24/7 Wall St. Closing Bell (AAPL, DELL, MOS, GILD, DNDN, BAS, CYH, LOPE, RRC, CETV, CHS, DLTR, GRMN, NG, RRD, TOL, HSTM, FIRE, THLD, NFX, CELL)

Top Analyst Upgrades & Downgrades (ASX, AAPL, BX, BRCM, CIEN, CMA, DELL, DNDN, DANG, GILD, MDT, MOS, EDU, SPIL, TSM)

XRP Holds Above $1 as Ripple Signs Korea’s First Regional Bank. Will It Move XRP?

Broadcom Falls 5% as Marvell Lands Google Custom Chip Deal, VMware and Financing Concerns Persist

He Worked 600 Hours of Wildfire Overtime at 64. He Thought the New Tax Break Would Protect His Social Security Check. He Was Wrong.

He Worked 600 Hours of Wildfire Overtime at 64. He Thought the New Tax Break Would Protect His Social Security Check. He Was Wrong.

One December Move Erases a Year of Missed Estimated Taxes: The IRS Treats RMD Withholding as Paid On Time, All Year Long.

XRP Holds Above $1 as Ripple Signs Korea’s First Regional Bank. Will It Move XRP?

Broadcom Falls 5% as Marvell Lands Google Custom Chip Deal, VMware and Financing Concerns Persist

Gilead Sciences : GILD

All Gilead Sciences Articles

BofA Adds GE, Gilead, Regions and Valero to Most Attractive Buy List

Short Interest in Biotech Wanes (ALXN, AMGN, ARNA, BIIB, CELG, DNDN, GILD, ILMN, ONXX, PCYC, REGN, VRTX, VVUS, IBB)

Media Digest (8/28/2012) Reuters, WSJ, NYT, Bloomberg

Biotech: Vertex and VIVUS Draw Short Interest (ALXN, AMGN, ARNA, BIIB, CELG, DNDN, GILD, ILMN, ONXX, PCYC, REGN, VRTX, VVUS)

Biotech: Dendreon and Regeneron Draw Short Interest

Top Analyst Upgrades and Downgrades (AMGN, AMT, AMAT, COH, DELL, FLEX, GILD, HPQ, KCG, LEAP, NTAP, SANM, SPLK, VE, VRTX, VVUS, WMT)

Gilead Options & New High In Stock Bring Hope For Further Upside

24/7 Wall St. Closing Bell — July 26, 2012: Market Jumps on ECB President’s Vow

How ‘At-Risk’ Is Gilead’s HIV/AIDS Drug Dominance? (GILD, MRK, GSK)

GlobeImmune Files For IPO, Cancer & Hepatitis with Great Partnerships

Key Biotech Issues To Watch (XBI, ANIK, BCRX, CBST, DNDN, GILD, ILMN, TRGT)

Abbott’s Hep-C Pressures All Hep-C Rivals (ABT, RIGL, GILD, VRTX, IDIX)

24/7 Wall St. Top Analyst Calls of the Week (BX, APO, CMA, DELL, DANG, EXM, FSLR, GILD, LVLT, ERIC, MAR, ORCL, SUN, VVUS, WBMD)

24/7 Wall St. Closing Bell (AAPL, DELL, MOS, GILD, DNDN, BAS, CYH, LOPE, RRC, CETV, CHS, DLTR, GRMN, NG, RRD, TOL, HSTM, FIRE, THLD, NFX, CELL)

Top Analyst Upgrades & Downgrades (ASX, AAPL, BX, BRCM, CIEN, CMA, DELL, DNDN, DANG, GILD, MDT, MOS, EDU, SPIL, TSM)

XRP Holds Above $1 as Ripple Signs Korea’s First Regional Bank. Will It Move XRP?

Broadcom Falls 5% as Marvell Lands Google Custom Chip Deal, VMware and Financing Concerns Persist

He Worked 600 Hours of Wildfire Overtime at 64. He Thought the New Tax Break Would Protect His Social Security Check. He Was Wrong.

Featured Reads

He Worked 600 Hours of Wildfire Overtime at 64. He Thought the New Tax Break Would Protect His Social Security Check. He Was Wrong.

One December Move Erases a Year of Missed Estimated Taxes: The IRS Treats RMD Withholding as Paid On Time, All Year Long.